Shionogi’s Osphena May Offer Safer Alternative To Estrogen

The first oral alternative to vaginal or oral steroidal estrogens for treatment of dyspareunia due to menopause appears to have lower risks of stroke and deep vein thrombosis, according to FDA labeling.

Shionogi Inc.’s Osphena (ospemifene) may offer an alternative to estrogen therapy for treatment of pain during sexual intercourse in postmenopausal women that carries a lower risk of blood clots.

More from United States

More from North America